Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Adderal/Dextrostat

Executive Summary

Explosion in pharmaceutical manufacturer Arenol's Sommerville, N.J. facility endangers supply of Adderall and Dextrostat, Shire's products for the treatment of attention deficit/hyperactivity disorder. Shire will either restart manufacturing at Arenol or transfer agreements to an alternative facility. Shire predicts sufficient supply for the next 3-4 months, but does not expect to re-establish a source of active ingredient before the exhaustion of currently available stocks. The supply halt will likely have an adverse effect on Shire's financial condition, as Adderall and Dextrostat represented 63% of Shire's revenue in the six months ended June 30
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS032649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel